Charles River Laboratories
627 hedge funds and large institutions have $10.4B invested in Charles River Laboratories in 2022 Q2 according to their latest regulatory filings, with 66 funds opening new positions, 263 increasing their positions, 218 reducing their positions, and 74 closing their positions.
21% more call options, than puts
Call options by funds: $33M | Put options by funds: $27.2M
21% more repeat investments, than reductions
Existing positions increased: 263 | Existing positions reduced: 218
1.59% more ownership
Funds ownership: 94.28% → 95.87% (+1.6%)
3% less funds holding
Funds holding: 644 → 627 (-17)
11% less first-time investments, than exits
New positions opened: 66 | Existing positions closed: 74
23% less capital invested
Capital invested by funds: $13.5B → $10.4B (-$3.1B)
43% less funds holding in top 10
Funds holding in top 10: 7 → 4 (-3)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$216M |
| 2 |
Allspring Global Investments
Charlotte,
North Carolina
|
+$149M |
| 3 |
JSP
Jackson Square Partners
Larkspur,
California
|
+$106M |
| 4 |
SCA
Southpoint Capital Advisors
New York
|
+$97.7M |
| 5 |
AI
Ariel Investments
Chicago,
Illinois
|
+$92.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$211M |
| 2 |
Massachusetts Financial Services
Boston,
Massachusetts
|
-$68.9M |
| 3 |
Millennium Management
New York
|
-$56M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$51M |
| 5 |
Victory Capital Management
San Antonio,
Texas
|
-$25.1M |
CRL Hedge Fund Activity: Q2 2022 in Review
627 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Charles River Laboratories (CRL) for Q2 2022, worth a combined $10.4B — down 23% from $13.5B a quarter earlier.
Sellers outnumbered buyers: 74 funds closed out of CRL and 66 opened new positions — a net loss of 8 holders — while 218 trimmed existing stakes and 263 added.
The largest buyer was T. Rowe Price Associates, adding an estimated $216M. The largest seller was Fidelity Investments, cutting an estimated $211M.
- 627 institutional investors held Charles River Laboratories (CRL) as of Q2 2022, down from 644 in Q1 2022.
- Funds reported $10.4B of Charles River Laboratories stock for Q2 2022, down 23% quarter-over-quarter.
- 66 funds opened new Charles River Laboratories positions in Q2 2022 and 74 closed out, a net change of -8 holders.
- The largest Charles River Laboratories buyer in Q2 2022 was T. Rowe Price Associates, an estimated $216M added.
- The largest Charles River Laboratories seller in Q2 2022 was Fidelity Investments, an estimated $211M sold.
Based on aggregated 13F filings for Q2 2022.